L3VLUP
ProSign in

NTLA · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NTLAVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NTLA
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterNTLAVRTX
Q3 20203 holders, $241m31 holders, $21.9bn
Q4 20209 holders, $709m30 holders, $18.4bn
Q1 202110 holders, $1.1bn31 holders, $15.4bn
Q2 202111 holders, $2.6bn30 holders, $12.7bn
Q3 202113 holders, $2.2bn35 holders, $10.1bn
Q4 202111 holders, $2.1bn28 holders, $12.4bn
Q1 20228 holders, $1.0bn23 holders, $16.1bn
Q2 20227 holders, $721m25 holders, $18.1bn
Q3 20227 holders, $892m22 holders, $18.4bn
Q4 20227 holders, $476m28 holders, $18.4bn
Q1 20237 holders, $575m26 holders, $21.4bn
Q2 20236 holders, $538m27 holders, $24.7bn
Q3 20234 holders, $366m33 holders, $24.3bn
Q4 20236 holders, $446m32 holders, $28.6bn
Q1 20247 holders, $412m31 holders, $29.8bn
Q2 20246 holders, $332m29 holders, $33.4bn
Q3 20245 holders, $310m27 holders, $33.5bn
Q4 20247 holders, $220m26 holders, $28.5bn
Q1 20253 holders, $110m21 holders, $35.4bn
Q2 20255 holders, $170m21 holders, $32.3bn
Q3 20257 holders, $333m22 holders, $25.9bn
Q4 20255 holders, $166m26 holders, $31.8bn
Q1 20265 holders, $342m25 holders, $31.8bn
Q2 20266 holders, $537m26 holders, $34.6bn
NTLA

Intellia Therapeutics Inc

Holders
5
Reported value
$342m
Buyers
18
Sellers
14

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NTLA (3)

ARK Investment Management LLC, PDT Partners LLC, Voloridge Investment Management LLC

Only VRTX (23)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →